Driving Innovation in TIL Therapy with a Pipeline Update from KSQ Therapeutics

  • Showcasing recent clinical data on the efficacy and safety of KSQ Therapeutics’ engineered TIL therapies across multiple cancer types
  • Exploring how gene-editing strategies are improving TIL function and persistence, with implications for more durable and effective patient outcomes